Abbrea Capital’s Novo Nordisk NVO Stock Holding History

Abbrea Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$377K	Sell	2,639 -647	-20%	-$85.7K	0.05%	178
2024 Q1	$425K	Hold	3,286	–	–	0.06%	184
2023 Q4	$340K	Sell	3,286 -150	-4%	-$14.8K	0.05%	195
2023 Q3	$312K	Buy	3,436 +152	+5%	+$13.4K	0.05%	190
2023 Q2	$266K	Sell	3,284 -100	-3%	-$8.17K	0.04%	204
2023 Q1	$271K	Hold	3,384	–	–	0.05%	199
2022 Q4	$229K	Buy	+3,384	New	+$198K	0.04%	212
2022 Q3	–	Sell	-3,614	Closed	-$201K	–	221
2022 Q2	$201K	Hold	3,614	–	–	0.03%	226
2022 Q1	$203K	Hold	3,614	–	–	0.03%	237
2021 Q4	$202K	Buy	+3,614	New	+$196K	0.03%	247

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Abbrea Capital's NVO Position: Q2 2024 in Review

Abbrea Capital reduced its Novo Nordisk (NVO) stake by 20% in Q2 2024, selling an estimated $85.7K and leaving 2,639 shares worth $377K. The position accounts for 0.05% of the portfolio, ranked #178.

Abbrea Capital first reported a position in NVO in Q4 2021 and has held it in 10 quarters since. The position peaked at $425K in Q1 2024. 1,864 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

Abbrea Capital held 2,639 shares of Novo Nordisk worth $377K as of Q2 2024.
Abbrea Capital sold 647 Novo Nordisk shares in Q2 2024, an estimated $85.7K.
Novo Nordisk made up 0.05% of Abbrea Capital's portfolio in Q2 2024, its #178 holding.
Abbrea Capital first reported a position in Novo Nordisk in Q4 2021 and has held it in 10 quarters since.
Abbrea Capital's Novo Nordisk position peaked at $425K in Q1 2024.
1,864 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.